Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT01831076

Completed

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

Breast Cancer | Stage II Breast Cancer | Stage III Breast Cancer
NCT03894007

Terminated

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer (PREDIXIIHER2)

HER2-positive Breast Cancer | Early-stage Breast Cancer
NCT02984683

Terminated

Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT02593227

Completed

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Breast Cancer
NCT04067102

Withdrawn

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

Triple Negative Breast Cancer
NCT00542191

Terminated

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Breast Cancer
NCT02685059

Completed

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)

Breast Cancer
NCT04405505

Unknown

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT04031703

Completed

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Breast Cancer
NCT04236310

Unknown

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Breast Cancer | HER2-positive Breast Cancer | ER-positive Breast Cancer
NCT03058939

Withdrawn

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

Breast Cancer | Breast Cancer Stage II | Breast Cancer Stage III
NCT03316794

Terminated

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Breast Cancer
NCT02470819

Withdrawn

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

Metastatic Breast Cancer | Breast Tumor | Advanced Gynecologic Cancer
NCT02347163

Terminated

Pre-operative Zoledronate in Triple Negative Breast Cancer

Breast Cancer
NCT02364960

Terminated

Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT) (TARGIT)

Early Stage Breast Cancer | Breast Tumor | Neoplasm of the Breast
NCT01094184

Completed

A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer (BATMAN)

Breast Cancer
NCT00016549

Completed

Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

Breast Cancer
NCT00344071

Completed

Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia

Inflammatory Breast Cancer
NCT01186991

Completed

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Breast Cancer
NCT02338531

Withdrawn

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer (RHEA)

Breast Cancer
NCT02511847

Unknown

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Triple Negative Breast Cancer
NCT02681562

Unknown

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Breast Cancer | Triple Negative Breast Cancer
NCT02616848

Unknown

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Triple Negative Breast Cancer
NCT02595138

Active, not recruiting

Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT01287624

Completed

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC) (TNBC)

Breast Cancer
NCT01434420

Unknown

Triple Negative Breast Cancer: Study of Molecular and Genetic Factors

Breast Cancer
NCT02001519

Completed

Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy (PACER)

Breast Cancer
NCT01969032

Completed

Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT01333137

Terminated

A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

Breast Cancer
NCT02115152

Unknown

Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer

Stage II Breast Cancer | Stage III Breast Cancer
NCT01880385

Unknown

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer (Beva)

Inflammatory Breast Cancer
NCT00773669

Completed

Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007

Breast Cancer
NCT04197687

Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma
NCT02780401

Completed

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (WOKVAC)

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu Negative | Stage III Breast Cancer | No Evidence of Disease
NCT01319539

Terminated

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative
NCT02682693

Completed

Denosumab as an add-on Neoadjuvant Treatment (GeparX) (GeparX)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III
NCT04086875

Active, not recruiting

A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8
NCT03106077

Completed

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8
NCT06434064

Recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Unresectable Triple-Negative Breast Carcinoma
NCT03941730

Active, not recruiting

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Advanced Triple-Negative Breast Carcinoma
NCT00343863

Completed

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Stage I Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Nausea and Vomiting
NCT06328465

Recruiting

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases (fREEDOM)

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer
NCT06263543

Recruiting

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC (SERIES)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Hormone-receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Low Breast Cancer
NCT05227664

Active, not recruiting

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Metastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast Cancer
NCT00513292

Completed

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | HER2/Neu Positive
NCT04445844

Active, not recruiting

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Triple-negative Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Breast Carcinoma
NCT03454529

Completed

The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer

Invasive Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7
NCT01754519

Terminated

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ
NCT03910712

Not yet recruiting

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (Pyrotinib)

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor
NCT00057941

Completed

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations